Financials
Financial year 2025
MANAGEMENT CONSULTING PHARMA from Perwez, company number BE1010773751, closed financial year 2025 with a result of € 101,238 after tax. For that financial year MANAGEMENT CONSULTING PHARMA recorded a gross margin of € 130,455 and equity of € 105,238. The company is profitable. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on December 4, 2025.
€ 105,238
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 101,238
Profit after tax over the fiscal year.
€ 84,308
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 101,238.
People and assets in 2025
≈ 1
No payroll staff. One director, so that person most likely runs the business.
€ 816
Book value of vehicles, furniture and equipment.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 2,062
Supplier invoices still open on the last day of the fiscal year.
€ 48,409
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
What happened to MANAGEMENT CONSULTING PHARMA?
What happened at MANAGEMENT CONSULTING PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 101,238. Source: NBB ↗
- New establishment in Perwez. KBO
- Start of the company according to the CBE. KBO
In short
Paid € 27,370 in corporate taxes since 2025.
A new publication or filing at MANAGEMENT CONSULTING PHARMA? We notify you, reason included.
Follow MANAGEMENT CONSULTING PHARMADatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind MANAGEMENT CONSULTING PHARMA is Gilles DE SCHEPPER.
Directors
According to the 2025 annual accounts
Gilles DE SCHEPPER
Director
Establishments
Establishment units
Physical locations of this company
Rue de Seumay 48
1360 Perwez
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 1010.773.751
- VAT number
- BE 1010.773.751
- Registered office
- Rue de Seumay 48, 1360 Perwez
- Names & denominations
- MANAGEMENT CONSULTING PHARMA
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 26 June 2024
- Peppol
- Active · Active since 4 Nov 2025
- Activities · NACE
Detailhandel in farmaceutische producten
Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies
Overige adviesbureaus op het gebied van bedrijfsbeheer; adviesbureaus op het gebied van bedrijfsvoering